Neumora Therapeutics shares are trading lower amid possible sympathy with Novo Nordisk after its ZEUS phase 3 trial did not translate into a MACE risk reduction.

Benzinga Newsdesk www.benzinga.com Negative 97.0%

Neg 97% Neu 0% Pos 0%

Comments

No comments yet. Be the first!